ID: MRFR/HC/6760-HCR | February 2021 | Region: Global | 111 pages
Global Musculoskeletal System Disorders Market is expected to cross USD 5.73 Billion by 2025 at a CAGR of 5.3%.
The number of musculoskeletal system disorder cases is increasing globally, fueling market growth. Musculoskeletal system disorders are the second-highest contributor to global disability and an estimated 20%–33% of people across the globe live with a painful musculoskeletal condition.
Musculoskeletal disorders are most common in low- and middle-income countries and these disorders require lifelong care to manage.
Rising prevalence of musculoskeletal disorders and increasing reimbursement offered to patients by health insurance providers.
By End User
Frequently Asked Questions (FAQ) :
The musculoskeletal system disorders market is projected to grow at a 5.3% CAGR between 2019-2025.
The Americas are predicted to have the largest share in the musculoskeletal system disorders market.
The musculoskeletal system disorders market is predicted to touch USD 5.73 billion by 2025.
Key competitors in the musculoskeletal system disorders market include GlaxoSmithKline PLC (UK), Baxter (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Eisai Co., Ltd (Japan), PhytoHealth Corporation (Taiwan), Tarsa Therapeutics, Inc. (US), OrthoTrophix, Inc. (US), LG Chem (South Korea), Lexicon Pharmaceuticals, Inc. (US), Amgen Inc. (US), Alder BioPharmaceuticals,Inc. (US), AbGenomics International, Inc. (US), and AB Science (France).
High surgery cost may restrict market growth.
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.